Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 2/20 | 0.43 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.33 |
| ▸ | XDH | P47989 | 1/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | CNR2 | P34972 | 2/20 | 0.32 |
| ▸ | PPARG | P37231 | 2/20 | 0.32 |
| ▸ | PPARD | Q03181 | 2/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.32 |
| ▸ | MAPT | P10636 | 2/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | ALDH2 | P05091 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bromide SCHEMBL14811828 | 0.98 | HDAC1 (0.42) | HDAC1HDAC4LMNAALDH1A1CYP3A4 | |
| SCHEMBL5129868 | 0.93 | HDAC1 (0.39) | HDAC1HDAC4LMNAALDH1A1CYP3A4 | |
| SCHEMBL5133383 | 0.86 | HDAC1 (0.35) | HDAC1HDAC4CNR2 | |
| SCHEMBL15174678 | 0.83 | HDAC1 (0.42) | HDAC1HDAC4LMNATSHRKDM4E | |
| SCHEMBL5130972 | 0.83 | HDAC1 (0.33) | HDAC1HDAC4CNR2 | |
| SCHEMBL5133137 | 0.79 | HDAC1 (0.31) | HDAC1HDAC4 | |
| SCHEMBL9331889 | 0.77 | HDAC1 (0.33) | HDAC1HDAC4KDM4EBCHEACHE | |
| SCHEMBL2730865 | 0.75 | ALDH1A1 (0.42) | ALDH1A1CYP3A4XDHTP53ALOX15 | |
| SCHEMBL15174190 | 0.74 | PABPC1 (0.44) | LMNAALDH1A1KDM4EKMT2A | |
| SCHEMBL16109052 | 0.74 | ALDH1A1 (0.34) | HDAC1HDAC4ALDH1A1CYP3A4XDH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2759016-B1 | ADDITIVES FOR HYDROGEN/ BROMINE CELLS | BROMINE COMPOUNDS LTD (IL) | 2017-03-29 | — | — | EP | claimed |
| EP-2953930-B1 | PROCESSES FOR PREPARING 1-ALKYL-3-ALKYL-PYRIDINIUM BROMIDE AND USES THEREOF AS ADDITIVES IN ELECTROCHEMICAL CELLS | BROMINE COMPOUNDS LTD (IL) | 2016-12-07 | — | — | EP | claimed |
| US-20080038123-A1 | Processing and/or operating machine comprising an ionic liquid as the operating liquid | MERCK PATENT GMBH (DE) | 2008-02-14 | — | — | US | claimed |
| CN-111418092-B | Nanostructured composite electrode | 科技创新动量基金(以色列)参股有限公司 | 2023-07-28 | — | — | CN | disclosed |
| CN-106083710-B | Process for the synthesis of halogenated cyclic compounds | 索尔维公司 | 2021-03-12 | — | — | CN | disclosed |
| EP-2334645-B1 | PROCESS FOR THE SYNTHESIS OF FLUORINATED CYCLIC COMPOUNDS | SOLVAY (BE) | 2019-11-06 | — | — | EP | disclosed |
| US-8981115-B2 | Process for the synthesis of halogenated cyclic compounds | SOLVAY SA (BE) | 2015-03-17 | — | — | US | disclosed |
| US-20130237710-A1 | Process for the synthesis of halogenated cyclic compounds | SOLVAY SA (BE) | 2013-09-12 | — | — | US | disclosed |
| US-8431710-B2 | Process for the synthesis of halogenated cyclic compounds | SOLVAY SA (BE) | 2013-04-30 | — | — | US | disclosed |
| US-20110178297-A1 | Process for the synthesis of halogenated cyclic compounds | SOLVAY SA (BE) | 2011-07-21 | — | — | US | disclosed |
| EP-2334645-A1 | PROCESS FOR THE SYNTHESIS OF HALOGENATED CYCLIC COMPOUNDS | Solvay SA (BE) | 2011-06-22 | — | — | EP | disclosed |
| WO-2010037688-A1 | PROCESS FOR THE SYNTHESIS OF HALOGENATED CYCLIC COMPOUNDS | SOLVAY SA (BE) | 2010-04-08 | — | — | WO | disclosed |
| EP-1644331-B1 | A METHOD FOR PRODUCING 1,3-DIALKYLPYRIDINIUM OLIGOMERS AND RELATED COMPOUNDS USING A SOLID SUPPORT | UNIV ABERDEEN (GB) | 2008-02-20 | — | — | EP | disclosed |
| US-20080038123-A1 | Processing and/or operating machine comprising an ionic liquid as the operating liquid | MERCK PATENT GMBH (DE) | 2008-02-14 | — | — | US | disclosed |
| US-20060217558-A1 | Method for producing 1, 3-dialkylpyridinium oligomers and related compounds using a solid support | ABERDEEN UNIVERSITY (GB) | 2006-09-28 | — | — | US | disclosed |
| US-20060217558-A1 | Method for producing 1, 3-dialkylpyridinium oligomers and related compounds using a solid support | ABERDEEN UNIVERSITY (GB) | 2006-09-28 | — | — | US | disclosed |
| EP-1644331-A1 | A METHOD FOR PRODUCING 1,3-DIALKYLPYRIDINIUM OLIGOMERS AND RELATED COMPOUNDS USING A SOLID SUPPORT | ABERDEEN UNIVERSITY (GB) | 2006-04-12 | — | — | EP | disclosed |
| WO-2004113299-A1 | A METHOD FOR PRODUCING 1, 3-DIALKYLPYRIDINIUM OLIGOMERS AND RELATED COMPOUNDS USING A SOLID SUPPORT | ABERDEEN UNIVERSITY (GB) | 2004-12-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110178297-A1 | Process for the synthesis of halogenated cyclic compounds | CCNL2, AOC2, CCNY | HDAC1 1967/4885HDAC4 2997/4885LMNA 1817/4885 |
| US-20130237710-A1 | Process for the synthesis of halogenated cyclic compounds | CCNL2, AOC2, CCNY | HDAC1 1967/4885HDAC4 2997/4885LMNA 1817/4885 |
| US-20060217558-A1 | Method for producing 1, 3-dialkylpyridinium oligomers and related compounds using a solid support | NCKAP1L, ATXN2L, RAD54L | HDAC1 4321/4885HDAC4 2797/4885LMNA 2430/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.